Generics Global Industry Guide 2015-2024

Generics Global Industry Guide 2015-2024

Summary

Global Generics industry profile provides top-line qualitative and quantitative summary information including: market size (value and volume 2015-19, and forecast to 2024). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.

Key Highlights

- For the purposes of this profile, a generic drug is defined as a copy of an ethical (prescription) drug formerly protected by patents that have now expired. Both unbranded generics and all branded generics are included. However, off-patent drugs that continue to be offered by the original manufacturer under the original name, and which form part of the generic-eligible market, are not included.
- The market value is evaluated at ex-factory prices.
- Market volume is quantified here as the percentage of the total ethical pharmaceutical market volume in a country or region which is accounted for by generic drugs. It is therefore a generics penetration rate measure, not an absolute measure of market volume.
- Regional volumes are calculated as weighted averages of countries which make up the region in question where volume data exists.
- Note that any volumes of "1" (one) or 100% are due to rounding as itdoes not believe that generics will ever fully represent 100% of the medicinal market in any country or region.
- All currency conversions were calculated at constant average annual 2019 exchange rates.
- Figures presented in this report are calculated applying the "middle path" scenario - this is based on the current situation in countries where the epidemic burst first, like China as a model countries and the announcements made by governments, stating that the abnormal situation may last up to six months.
- The assumption has been made that after this time the economy will gradually go back to the levels recorded before the pandemics by the end of the year. It is also assumed that there is no widespread economic crisis as seen back in 2008 due to announced pay-outs across countries.
- At the moment of preparation of this report in July 2020 the economic implications of the lock downs of many economics are still very difficult to predict as there is no indication how long the pandemics could last, the number of sectors forced to stay closed and the scale of the governmental aid involved.
- The global generics market had total revenues of $339.2bn in 2019, representing a compound annual growth rate (CAGR) of 6.1% between 2015 and 2019.
- Market consumption volume increased with a CAGR of 2.4% between 2015 and 2019, to reach a total of 54.6% in 2019.
- Asia-Pacific accounts for 38.3% of the global market value whilst Europe and the US make up 22.1% and 32.1% respectively.

Scope

- Save time carrying out entry-level research by identifying the size, growth, and leading players in the global generics market
- Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the global generics market
- Leading company profiles reveal details of key generics market players global operations and financial performance
- Add weight to presentations and pitches by understanding the future growth prospects of the global generics market with five year forecasts by both value and volume

Reasons to Buy

- What was the size of the global generics market by value in 2019?
- What will be the size of the global generics market in 2024?
- What factors are affecting the strength of competition in the global generics market?
- How has the market performed over the last five years?
- How large is the global generics market in relation to its regional counterparts?

1 EXECUTIVE SUMMARY
1.1. Market value
1.2. Market value forecast
1.3. Market volume
1.4. Market volume forecast
1.5. Geography segmentation
1.6. Competitive Landscape
2 Introduction
2.1. What is this report about?
2.2. Who is the target reader?
2.3. How to use this report
2.4. Definitions
3 Global Generics
3.1. Market Overview
3.2. Market Data
3.3. Market Segmentation
3.4. Market outlook
3.5. Five forces analysis
3.6. Macroeconomic Indicators
4 Generics in Asia-Pacific
4.1. Market Overview
4.2. Market Data
4.3. Market Segmentation
4.4. Market outlook
4.5. Five forces analysis
5 Generics in Europe
5.1. Market Overview
5.2. Market Data
5.3. Market Segmentation
5.4. Market outlook
5.5. Five forces analysis
5.6. Macroeconomic Indicators
6 Generics in France
6.1. Market Overview
6.2. Market Data
6.3. Market Segmentation
6.4. Market outlook
6.5. Five forces analysis
6.6. Macroeconomic Indicators
7 Generics in Germany
7.1. Market Overview
7.2. Market Data
7.3. Market Segmentation
7.4. Market outlook
7.5. Five forces analysis
7.6. Macroeconomic Indicators
8 Generics in Italy
8.1. Market Overview
8.2. Market Data
8.3. Market Segmentation
8.4. Market outlook
8.5. Five forces analysis
8.6. Macroeconomic Indicators
9 Generics in Japan
9.1. Market Overview
9.2. Market Data
9.3. Market Segmentation
9.4. Market outlook
9.5. Five forces analysis
9.6. Macroeconomic Indicators
10 Generics in Australia
10.1. Market Overview
10.2. Market Data
10.3. Market Segmentation
10.4. Market outlook
10.5. Five forces analysis
10.6. Macroeconomic Indicators
11 Generics in Canada
11.1. Market Overview
11.2. Market Data
11.3. Market Segmentation
11.4. Market outlook
11.5. Five forces analysis
11.6. Macroeconomic Indicators
12 Generics in China
12.1. Market Overview
12.2. Market Data
12.3. Market Segmentation
12.4. Market outlook
12.5. Five forces analysis
12.6. Macroeconomic Indicators
13 Generics in The Netherlands
13.1. Market Overview
13.2. Market Data
13.3. Market Segmentation
13.4. Market outlook
13.5. Five forces analysis
13.6. Macroeconomic Indicators
14 Generics in Spain
14.1. Market Overview
14.2. Market Data
14.3. Market Segmentation
14.4. Market outlook
14.5. Five forces analysis
14.6. Macroeconomic Indicators
15 Generics in The United Kingdom
15.1. Market Overview
15.2. Market Data
15.3. Market Segmentation
15.4. Market outlook
15.5. Five forces analysis
15.6. Macroeconomic Indicators
16 Generics in The United States
16.1. Market Overview
16.2. Market Data
16.3. Market Segmentation
16.4. Market outlook
16.5. Five forces analysis
16.6. Macroeconomic Indicators
17 Company Profiles
17.1. Teva Pharmaceutical Industries Limited
17.2. Pfizer Inc.
17.3. Sun Pharmaceutical Industries Ltd
17.4. Mylan N.V.
17.5. Sanofi SA
17.6. Les Laboratoires Servier
17.7. STADA Arzneimittel AG
17.8. Daiichi Sankyo Co Ltd
17.9. Sawai Pharmaceutical Co Ltd
17.10. Lupin Ltd
17.11. Aspen Pharmacare Holdings Ltd
17.12. Apotex, Inc.
17.13. China Grand Pharmaceutical and Healthcare Holdings Limited
17.14. Esteve Group
18 Appendix
18.1. Methodology
18.2. About MarketLine

List Of Tables

Table 1: Global generics market value: $ billion, 201519
Table 2: Global generics market volume: % of total pharma, 201519
Table 3: Global generics market geography segmentation: $ billion, 2019
Table 4: Global generics market value forecast: $ billion, 201924
Table 5: Global generics market volume forecast: % of total pharma, 201924
Table 6: Global size of population (million), 201519
Table 7: Global gdp (constant 2005 prices, $ billion), 201519
Table 8: Global gdp (current prices, $ billion), 201519
Table 9: Global inflation, 201519
Table 10: Global consumer price index (absolute), 201519
Table 11: Global exchange rate, 201519
Table 12: Asia-Pacific generics market value: $ billion, 201519
Table 13: AsiaPacific generics market volume: % of total pharma, 201519
Table 14: AsiaPacific generics market geography segmentation: $ billion, 2019
Table 15: Asia-Pacific generics market value forecast: $ billion, 201924
Table 16: AsiaPacific generics market volume forecast: % of total pharma, 201924
Table 17: Europe generics market value: $ billion, 201519
Table 18: Europe generics market volume: % of total pharma, 201519
Table 19: Europe generics market geography segmentation: $ billion, 2019
Table 20: Europe generics market value forecast: $ billion, 201924
Table 21: Europe generics market volume forecast: % of total pharma, 201924
Table 22: Europe size of population (million), 201519
Table 23: Europe gdp (constant 2005 prices, $ billion), 201519
Table 24: Europe gdp (current prices, $ billion), 201519
Table 25: Europe inflation, 201519
Table 26: Europe consumer price index (absolute), 201519
Table 27: Europe exchange rate, 201519
Table 28: France generics market value: $ million, 201519
Table 29: France generics market volume: % of total pharma, 201519
Table 30: France generics market geography segmentation: $ million, 2019
Table 31: France generics market value forecast: $ million, 201924
Table 32: France generics market volume forecast: % of total pharma, 201924
Table 33: France size of population (million), 201519
Table 34: France gdp (constant 2005 prices, $ billion), 201519
Table 35: France gdp (current prices, $ billion), 201519
Table 36: France inflation, 201519
Table 37: France consumer price index (absolute), 201519
Table 38: France exchange rate, 201519
Table 39: Germany generics market value: $ billion, 201519
Table 40: Germany generics market volume: % of total pharma, 201519
Table 41: Germany generics market geography segmentation: $ billion, 2019
Table 42: Germany generics market value forecast: $ billion, 201924
Table 43: Germany generics market volume forecast: % of total pharma, 201924
Table 44: Germany size of population (million), 201519
Table 45: Germany gdp (constant 2005 prices, $ billion), 201519
Table 46: Germany gdp (current prices, $ billion), 201519
Table 47: Germany inflation, 201519
Table 48: Germany consumer price index (absolute), 201519
Table 49: Germany exchange rate, 201519
Table 50: Italy generics market value: $ million, 201519

List Of Figures

Figure 1: Global generics market value: $ billion, 201519
Figure 2: Global generics market volume: % of total pharma, 201519
Figure 3: Global generics market geography segmentation: % share, by value, 2019
Figure 4: Global generics market value forecast: $ billion, 201924
Figure 5: Global generics market volume forecast: % of total pharma, 201924
Figure 6: Forces driving competition in the global generics market, 2019
Figure 7: Drivers of buyer power in the global generics market, 2019
Figure 8: Drivers of supplier power in the global generics market, 2019
Figure 9: Factors influencing the likelihood of new entrants in the global generics market, 2019
Figure 10: Factors influencing the threat of substitutes in the global generics market, 2019
Figure 11: Drivers of degree of rivalry in the global generics market, 2019
Figure 12: Asia-Pacific generics market value: $ billion, 201519
Figure 13: AsiaPacific generics market volume: % of total pharma, 201519
Figure 14: AsiaPacific generics market geography segmentation: % share, by value, 2019
Figure 15: Asia-Pacific generics market value forecast: $ billion, 201924
Figure 16: AsiaPacific generics market volume forecast: % of total pharma, 201924
Figure 17: Forces driving competition in the generics market in Asia-Pacific, 2019
Figure 18: Drivers of buyer power in the generics market in Asia-Pacific, 2019
Figure 19: Drivers of supplier power in the generics market in Asia-Pacific, 2019
Figure 20: Factors influencing the likelihood of new entrants in the generics market in Asia-Pacific, 2019
Figure 21: Factors influencing the threat of substitutes in the generics market in Asia-Pacific, 2019
Figure 22: Drivers of degree of rivalry in the generics market in Asia-Pacific, 2019
Figure 23: Europe generics market value: $ billion, 201519
Figure 24: Europe generics market volume: % of total pharma, 201519
Figure 25: Europe generics market geography segmentation: % share, by value, 2019
Figure 26: Europe generics market value forecast: $ billion, 201924
Figure 27: Europe generics market volume forecast: % of total pharma, 201924
Figure 28: Forces driving competition in the generics market in Europe, 2019
Figure 29: Drivers of buyer power in the generics market in Europe, 2019
Figure 30: Drivers of supplier power in the generics market in Europe, 2019
Figure 31: Factors influencing the likelihood of new entrants in the generics market in Europe, 2019
Figure 32: Factors influencing the threat of substitutes in the generics market in Europe, 2019
Figure 33: Drivers of degree of rivalry in the generics market in Europe, 2019
Figure 34: France generics market value: $ million, 201519
Figure 35: France generics market volume: % of total pharma, 201519
Figure 36: France generics market geography segmentation: % share, by value, 2019
Figure 37: France generics market value forecast: $ million, 201924
Figure 38: France generics market volume forecast: % of total pharma, 201924
Figure 39: Forces driving competition in the generics market in France, 2019
Figure 40: Drivers of buyer power in the generics market in France, 2019
Figure 41: Drivers of supplier power in the generics market in France, 2019
Figure 42: Factors influencing the likelihood of new entrants in the generics market in France, 2019
Figure 43: Factors influencing the threat of substitutes in the generics market in France, 2019
Figure 44: Drivers of degree of rivalry in the generics market in France, 2019
Figure 45: Germany generics market value: $ billion, 201519
Figure 46: Germany generics market volume: % of total pharma, 201519
Figure 47: Germany generics market geography segmentation: % share, by value, 2019
Figure 48: Germany generics market value forecast: $ billion, 201924
Figure 49: Germany generics market volume forecast: % of total pharma, 201924
Figure 50: Forces driving competition in the generics market in Germany, 2019

Fill The Form For Sample Request

Full Name*

Business Email *

E-mail

Country *

Select Country Albania Algeria Afghanistan Angola Argentina Armenia Aruba Australia Austria Azerbaijan Andorra Anguilla Bahrain Bangladesh Barbados Belarus Belgium Benin Bermuda Bhutan Bolivia Bosnia and Herzegovina Botswana Brazil Brunei Bulgaria Burkina Faso Burundi Bosnia Cambodia Cameroon Central African Republic Chad Chile China Colombia Comoros Congo (Brazzaville) Cook Islands Costa Rica Cote d Ivoire Croatia Cuba Cyprus Czech Republic Cayman Islands Denmark Djibouti Dominican Republic Ecuador Egypt El Salvador Equatorial Guinea Eritrea Estonia Ethiopia Fiji Finland France Gabon Gambia Georgia Germany Ghana Gibraltar Greece Guam Guatemala Guernsey Guinea Guinea-Bissau Guyana Haiti Honduras Hong Kong Hungary Herzegovina Iceland India Indonesia Iran Iraq Ireland Isle of Man Israel Italy Jamaica Japan Jersey Jordan Kazakhstan Kenya Kiribati Kuwait Korea Kyrgyzstan Laos Latvia Lebanon Lesotho Liberia Libya Lithuania Luxembourg Liechtenstein Macau Macedonia Madagascar Malawi Malaysia Maldives Mali Malta Marshall Islands Mauritania Mauritius Mexico Moldova Monaco Mongolia Montenegro Morocco Mozambique Myanmar Middle East & North Africa (MENA) Namibia Nauru Nepal Netherlands New Caledonia New Zealand Nicaragua Niger Nigeria North Korea Norway Oman Pakistan Palau Palestinian Territories Panama Papua New Guinea Paraguay Peru Philippines Poland Portugal Puerto Rico Palestine Qatar Romania Russia Rwanda Samoa Saudi Arabia Senegal Serbia Seychelles Sierra Leone Singapore Slovakia Slovenia Solomon Islands Somalia South Africa South Korea Spain Sri Lanka Saint Kitts and Nevis Saint Vincent and the Grenadines Sudan Suriname Swaziland Sweden Switzerland Syria Scotland San Marino Taiwan Tajikistan Tanzania Thailand Timor-Leste Togo Tonga Trinidad and Tobago Tunisia Turkey Turkmenistan Turks and Caicos Islands Tuvalu Uganda Ukraine United Arab Emirates United Kingdom United States of America Uruguay Uzbekistan Uraguay Vanuatu Venezuela Vietnam Virgin Islands Yemen Zambia Zimbabwe Canada Grenada Cape Verde Belize Curacao Republic of Srpska Antigua and Barbuda Saint Lucia Falkland Islands Faroe Islands Federated States of Micronesia Guadeloupe Martinique Montserrat Niue

Contact No *

Alternate No

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available